Loren D Walensky

This inventor holds 58 USPTO granted patents and 37 published patent applications, plus 10 CIPO patents and 28 EPO patents, primarily in Stabilized Peptides. Top assignees: Dana-Farber-Cancer Institute Inc., Harvard College, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Loren D Walensky. Retrieved from https://idiyas.com/inventor/loren-d-walensky

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 58 (Patent Applications = 37)

% Patents Active = 89.7

CIPO Patents = 10 (Patent Applications = 9)

EPO Patents = 28 (Patent Applications = 48)

Average Co-Inventor Count = 2.7

ph-index = 10

Forward Citations = 553(Granted Patents)

Forward Citations (Not Self Cited) = 448(Dec 10, 2025)

Location History:

Newton Centre, MA (US) (2016 - 2019)
Chestnut Hill, MA (US) (2010 - 2020)
Newton Center, MA (US) (2020)
Pelham, MA (US) (2021)
Newton, MA (US) (2015 - 2024)

Company Filing History:

54 out of 1,268

Dana-Farber-Cancer Institute Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 1 out of 44

Aileron Therapeutics, Inc.

patents

5. 1 out of 8,586

Massachusetts Institute of Technology

The University of Chicago

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Stabilized Peptides

Targeting Wnt Signaling

Antimicrobial Peptides

Apoptosis Proteins

Fatty Acid Metabolism

Cancer Therapies

Cellular Homeostasis

BCL-9

BH4 Peptides

Quantitative Mass Spectrometry

Peptide Modules

EZH2 Peptides

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753208 - ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF (2026-10-06),

2. 12570698 - STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN (2026-03-10),

3. 12534501 - TARGETING DEREGULATED WNT SIGNALING IN CANCER USING STABILIZED ALPHA-HELICES OF BCL-9 (2026-01-27),

4. 12528846 - BH4 Stabilized Peptides And Uses Thereof (2026-01-20),

5. 12466853 - SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES (2025-11-11),

6. 12441775 - BCL-W polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss (2025-10-14),

7. 12391733 - Stapled intracellular-targeting antimicrobial peptides to treat infection (2025-08-19),

8. 12387815 - Visual representations of peptide sequences (2025-08-12),

9. 12366576 - Compositions, assays, and methods for direct modulation of fatty acid metabolism (2025-07-22),

10. 12358960 - Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides (2025-07-15),

11. 12344643 - Compositions and methods for inhibition of FOXP3 (2025-07-01),

12. 12153051 - Reagents for quantitative mass spectrometry (2024-11-26),

13. 11982674 - Reagents for quantitative mass spectrometry (2024-05-14),

14. 11952432 - Cell-permeable stapled peptide modules for cellular delivery (2024-04-09),

15. 11945846 - Stapled intracellular-targeting antimicrobial peptides to treat infection (2024-04-02),

Title: The Innovative Journey of Loren D Walensky

Introduction: Loren D Walensky, a distinguished inventor hailing from Newton, MA, has made significant contributions to the field of science and technology through his groundbreaking innovations.

Latest Patents: Walensky holds several patents in the areas of biotechnology and medical research, with his most recent patent focusing on a novel method for targeted cancer therapy using nanotechnology.

Career Highlights: With a background in biochemistry and molecular pharmacology, Walensky has had a prolific career marked by pioneering research in developing new treatments for various diseases, particularly cancer. His work has been instrumental in advancing the field of precision medicine.

Collaborations: Throughout his career, Walensky has collaborated with leading researchers, pharmaceutical companies, and academic institutions to further his research and bring his inventions to the market. His collaborative efforts have resulted in innovative solutions with the potential to revolutionize healthcare.

Conclusion: Loren D Walensky's dedication to scientific discovery and commitment to improving patient outcomes have solidified his reputation as a visionary inventor in the field of biotechnology. His innovative approach to targeted therapy has the potential to transform the landscape of cancer treatment, offering hope to patients worldwide.

Profile summary based on public USPTO records.